Celgene Gets CHMP Positive Opinions for Revlimid, Imnovid Combos in Multiple Myeloma

By Colin Kellaher

Celgene Corp. (CELG) on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use adopted positive opinions for a pair of triplet regimens based on its Revlimid and Imnovid medications in multiple myeloma.

The Summit, N.J., biopharmaceutical company said the panel recommended European Commission approval of Revlimid in combination with bortezomib and dexamethasone in adults with previously untreated multiple myeloma who aren't eligible for transplant.

Celgene, which in January announced a deal to be acquired by Bristol-Myers Squibb Co. (BMY), said the CHMP also recommended approval of Imnovid in combination with bortezomib and dexamethasone for adults with multiple myeloma who have received at least one prior treatment regimen including lenalidomide.

Multiple myeloma is a cancer that forms in a type of white blood cells called plasma cells and causes cancer cells to accumulate in the bone marrow.

Celgene said the European Commission, which generally follows the CHMP's recommendations, is expected to make its final decision in about two months.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

March 29, 2019 08:54 ET (12:54 GMT)

Celgene (NASDAQ:CELG)
Historical Stock Chart
From Jun 2024 to Jul 2024